Company Overview
Cobra has three GMP approved facilities in Sweden and the UK, each with specific expertise tailored to serving our customers around the world. We offer a broad range of integrated and stand-alone contract development and manufacturing services for clinical trials and the commercial market.

As a trusted provider and a key partner in the drug development and commercialisation process, we take pride in our manufacturing excellence and comprehensive range of services to the pharmaceutical and biotech industries.

Cobra is a Contract Development and Manufacturing Organisation (CDMO) supporting the global life sciences industry in the development and manufacture of monoclonal antibodies (mAb), recombinant proteins, DNA, viral vectors, microbiota and cell line derived products and pharmaceuticals for clinical trials and commercial supply.

Over 18 years of track record in producing biologics and pharmaceuticals for use in pre-clinical to Phase III clinical trials and commercial supply has given our people a unique knowledge base as both manufacturer and also as service providers for the global life sciences market.

We offer a broad range of integrated and stand-alone development services, bespoke to individual customer requirements, stretching from cell line development to the supply of investigational medicinal product for clinical trials and commercial market supply.

Every program complies with cGMP standards worldwide and is conceived with an unmatched quality derived from the know-how of Cobra’s highly qualified, flexible and dedicated people.

Cobra has three GMP approved facilities; in Sweden our Microbiota Production and Fill Finish Facility in Matfors, and our Biosimilar and Antibody Production Facility in Södertälje, and in the United Kingdom our Centre of Excellence for Gene Therapy located in Keele. Our sites offer a comprehensive service to nurture your project from conception to fill and finish.